|Bid||82.65 x 1100|
|Ask||82.88 x 900|
|Day's Range||81.67 - 82.80|
|52 Week Range||72.23 - 92.64|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||21.69|
|Earnings Date||Apr 27, 2020|
|Forward Dividend & Yield||2.44 (2.98%)|
|Ex-Dividend Date||Mar 12, 2020|
|1y Target Est||97.94|
ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification
Global equities are reeling as the coronavirus from China continues to spread globally, killing its first victim in Japan. The outbreak is also forcing China to choose between killing its economy or killing more citizens by sending people back to work too early. Add to that reports the U.S. military is preparing quarantine facilities on bases and people are suddenly feeling fearful again.No surprise then that the Dow Jones Industrial Average is stalling just below the 30,000 level and looks set for another test of its 200-day moving average last touched back in October. Here are three stocks that are already rolling over.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dow Jones Stocks: 3M (MMM)Source: Chart courtesy of StockCharts.com3M (NYSE:MMM) shares are rolling over after the company reported disappointing earnings despite a 2.1% increase in sales from the prior year period. And mixed forward guidance only added to the pressure. The company is feeling the pressure from the going ons in China because of its exposure to the automotive sector, where it provides things like acoustic systems. Thus, the company's transportation and electronics segment saw a 5.9% drop in sales.Management is responding with job cuts to bolster profitability, but cost cutting is always a bad look especially when years of top-line growth have spoiled investors. This was bad timing for the folks at Wolfe Research, who just upgraded the stock to "neutral." Johnson & Johnson (JNJ)Source: Chart courtesy of StockCharts.comShares of healthcare icon Johnson & Johnson (NYSE:JNJ) are threatening to fall below their 20-day moving average. Such a fall would break the post-October uptrend the stock has enjoyed as consumer health claims continue to dent sentiment. A New Jersey state jury recently ordered the company to pay $750 million in punitive damages to four plaintiffs. Legal headwinds also remain from opioid and antipsychotic medications.Investors are also feeling sour after a mixed earnings report at the end of January. Sales of baby products in the United States -- a key retail category for the company and a source of a lot of brand goodwill -- fell nearly 27% year-over-year. Merck (MRK)Source: Chart courtesy of StockCharts.comMerck (NYSE:MRK) shares have fallen below their 200-day moving average, breaking an uptrend pattern going back to early 2018. This looks like classic profit taking as the company just reported solid earnings. But why all the selling? The pharmaceutical company reported revenue rising nearly 8% year-over-year on a 7% increase in pharmaceutical sales.Well, Vermont Sen. Bernie Sanders' win in the New Hampshire primary could be a concern. Sanders has been a vocal critic of drug prices and an advocate for single-payer healthcare in the United States. President Donald Trump, in his State of the Union address, also called for a "bipartisan legislation on drug prices." That's probably the only thing Sanders and Trump would ever agree on: Prescription drug prices are too high.As of this writing, William Roth does not hold any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 20 Stocks to Buy From the Law of Accelerating Returns * 10 Strong Lottery Ticket Stocks That Could Soar in 2020 * 7 U.S. Stocks to Buy on Coronavirus Weakness The post 3 Dow Jones Industrial Average Stocks to Sell appeared first on InvestorPlace.
(Bloomberg) -- Merck & Co. stock fell to a three-month low on Wednesday after what appeared to be promising data in an aggressive form of breast cancer. But it’s not the data moving shares, Evercore ISI told investors.Instead that as much as 2.5% drop was driven by a rotation away from Merck and into “another large cap pharma name,” Umer Raffat concluded. Evercore declined to comment on which peer it was, saying it was restricted on that stock.That leaves open the door to a number of possibilities as health-care traders pointed to a move away from long investments and toward crowded short names like AbbVie Inc. or Bristol-Myers Squibb Co. Both those companies have more than twice the notional short interest than Merck’s $2.1 billion, according to data from S3 Partners. Evercore suspended coverage on AbbVie last year and has been advising the drugmaker on its deal for Allergan Plc.Technicals could also be spurring the move lower after Merck dropped below its 200-daily moving average Wednesday. The stock has fallen 5.7% since announcing plans for a spinoff last week that analysts warned would only increase its reliance on its top-selling drug Keytruda.To contact the reporter on this story: Cristin Flanagan in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Jennifer Bissell-LinskFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Merck’s KEYTRUDA in Combination with Chemotherapy Met Primary Endpoint of PFS as First-Line Treatment for Metastatic Triple-Negative Breast Cancer
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...
When Jan Skvarka joined Cambridge’s Trillium Therapeutics as CEO in September 2019, the company had a paltry market cap of $27 million and had been stuck in a drug development rut. Months later, the company may be bouncing back.
Biotech stocks recovered last week along with the broader markets, which bounced back from a China coronavirus-induced sell-off. Big pharma earnings took the spotlight, with Merck & Co., Inc. (NYSE: MRK ...
The yearly results for Merck & Co., Inc. (NYSE:MRK) were released last week, making it a good time to revisit its...
Noted financial-accounting expert Bob Willens highlights several tax issues of growing importance to his clientele, as well as recent changes in the tax code that could confound—or reward—investors.
The spreading coronavirus epidemic will disrupt supply chains and reduce surgeries. So far, the costs don’t look all that threatening. But as the crisis grows, the effects will be felt across the global economy.
(Bloomberg) -- Merck & Co.’s plan to spin off its women’s health and biosimilar medicines units is sparking debate about its dependence on its top-selling drug among Wall Street analysts.The move to shed assets will further increase the drugmaker’s reliance on its blockbuster cancer medicine -- Keytruda -- and that’s not sitting well with some. That strategy may fuel a bulls vs bears controversy as Keytruda faces off against lower-priced competition in China and trial results may challenge the medicine’s supremacy in the U.S.A once “easy to own” story introduces a “valuation debate into a well-owned stock,” RBC analyst Randall Stanicky cautioned. “While perhaps unfair, we expect Keytruda concentration to become a bigger theme into competitor data that, while lower-risk, will add questions,” he wrote to clients in a note.Stanicky is one of four of the 20 analysts tracked by Bloomberg who remain neutral on Merck. He trimmed his share price target on the sector perform-rated company to $92 from $99. The company’s stock has dropped over 3% since it announced the spinoff.Even before Merck announced the new set up and ahead of Thursday night’s earnings SVB Leerink analyst Daina Graybosch voiced her concerns about Keytruda drawing political scrutiny during an election year after it overtook Revlimid last year to be the world’s top-selling cancer medicine. Bloomberg compiled sales estimates show Keytruda is on pace to overtake AbbVie Inc.’s Humira as the world’s top-selling medicine in 2023.“Investors have been wary of companies that rely on a single-product,” and Keytruda is set to become half of Merck’s sales by 2027 or 2028, she wrote earlier today.Competitive results -- like those from a kidney cancer drug combination from Bristol-Myers Squibb and Exelixis Inc. expected in the first quarter -- could hurt Keytruda’s dominance if they are able to demonstrate more efficacy, she said. Despite potential Keytruda “roadblocks” Graybosch kept her outperform rating while trimming her share price forecast to $100 from $103 on reimbursement concerns outside the U.S.Morgan Stanley’s David Risinger remained bullish: “Although Keytruda faces competitive threats, we assume that Keytruda’s efficacy bar remains difficult to beat. If there is a novel therapy that outperforms Keytruda some day, that regimen would likely carry additional toxicity...which would likely raise questions about its benefit-risk ratio.”Risinger took down his price target by $4 to $97. The current average price target of $99 implies Merck shares may advance 15% over the next year.(Updates to add chart)\--With assistance from David Tung, Tara Israel and Michael J. Burdette.To contact the reporter on this story: Cristin Flanagan in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Divya Balji, Scott SchnipperFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Bristol-Myers Squibb Co said on Thursday its operating profit rose by around a third from a year ago because fourth-quarter results included some revenue from Celgene, which the U.S. drugmaker bought in a $74 billion deal that closed in late November. Bristol-Myers said on an operating basis it earned $1.22 a share on $7.95 billion of revenue in the quarter. The results included Celgene revenue beginning Nov. 20.
Moody's Investors Service ("Moody's") affirmed the ratings of Merck & Co., Inc. ("Merck") including the A1 senior unsecured long-term rating and the Prime-1 short-term rating. The rating affirmation follows the announcement that Merck intends to spin-off products from its Women's Health, Legacy Brands, and Biosimilars businesses (collectively known as "NewCo") into an independent public company. The transaction is expected to close in the first half of 2021 and result in a tax-free dividend payment to Merck of approximately $8 billion to $9 billion.
STOCKSTOWATCHTODAY BLOG Three numbers to start your day: Casper Sleep is Now Seeks An About $500 Million Public Market Value On Wednesday, the start-up lowered the price range on its IPO by almost a third.
The following are the top stories in the Wall Street Journal. - Casper Sleep Inc priced its initial public offering at the low end of its already slashed range at $12 on Wednesday, the latest sign that the path to public ownership remains treacherous for unprofitable startups. - Jeff Weiner, the chief executive officer of Microsoft Corp's LinkedIn, will step down in June, Weiner said in a post on the professional networking platform on Wednesday, as the software giant also restructures other elements of its operation.